TScan Therapeutics Restructures, Cuts Workforce by 75% to Focus on Solid Tumor Program
TScan Therapeutics (NASDAQ:TCRX) announced a major restructuring that includes cutting its workforce by approximately 75%. The move is part of the company's strategy shift toward an in vivo-engineered T cell receptor program targeting solid tumors. Two product candidates, one targeting PRAME and another MAGE-A4, are expected to enter investigational new drug-enabling studies. The reorganization aims to generate $55 million in cost savings through 2027, with the company's current cash reserves projected to last until late 2027. TScan has also paused enrollment in its Phase 3 ALLOHA-2 study due to insufficient capital but will continue monitoring seven enrolled patients and is seeking strategic partners for further development. TScan reported positive data from Cohort C of its Phase 1 ALLOHA trial, where all 13 monitored patients showed complete donor chimerism. The company plans additional updates in late 2026 and early 2027.
Tickers: $TCRX
Topics: biotech layoffs restructuring solid tumors TCR-T therapy